Guardant Health Shares Outstanding 2017-2022 | GH
Guardant Health shares outstanding from 2017 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Guardant Health Annual Shares Outstanding (Millions of Shares) |
2021 |
101 |
2020 |
98 |
2019 |
91 |
2018 |
30 |
2017 |
13 |
2016 |
13 |
Guardant Health Quarterly Shares Outstanding (Millions of Shares) |
2022-03-31 |
102 |
2021-12-31 |
101 |
2021-09-30 |
101 |
2021-06-30 |
101 |
2021-03-31 |
101 |
2020-12-31 |
98 |
2020-09-30 |
100 |
2020-06-30 |
96 |
2020-03-31 |
94 |
2019-12-31 |
91 |
2019-09-30 |
93 |
2019-06-30 |
89 |
2019-03-31 |
86 |
2018-12-31 |
30 |
2018-09-30 |
13 |
2018-06-30 |
12 |
2018-03-31 |
12 |
2017-12-31 |
|
2017-09-30 |
12 |
2016-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$3.799B |
$0.374B |
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
|